drugset / Trial / NCT06585163
Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension
Phase 1
Not yet recruiting
8 enrolled
Quivive Pharma, Inc.
National Institute on Drug Abuse (NIDA) · collab
RandomizedCrossoverTriple-blindSupportive care
Summary
This study has been designed to assess the safety, tolerability, and pharmacokinetics of a therapeutic dose of hydrocodone bitartrate with and without an oral dose of doxapram hydrochloride in healthy volunteers who are naltrexone-blocked.
Timeline
- Start
- 2024-09
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxapram | Small molecule | — | Oral |
| Subject | hydrocodone bitartrate | Unknown | — | Oral |
Indications
No indication recorded.